Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed metastatic adenocarcinoma of the pancreas
• * Progressed after first-line or adjuvant gemcitabine-based chemotherapy
• Measurable disease as assessed by RECIST criteria
• No known brain metastasis or symptomatic carcinomatous leptomeningitis
• PATIENT CHARACTERISTICS:
• WHO performance status 0-1
• Life expectancy ≥ 3 months
• ANC ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9 g/dL
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Total bilirubin ≤ 2.5 times ULN
• ALT/AST ≤ 5 times ULN
• LVEF ≥ 55%
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No significant comorbidities, including any of the following:
• * Cardiovascular disease
• * Documented history of congestive heart failure
• * Uncontrolled, high-risk arrhythmia
• * Angina pectoris requiring treatment
• * Clinically significant valvular disease
• * Evidence of transmural myocardial infarction by ECG
• * Uncontrolled hypertension
• * Active bleeding
• * Clinically significant active infection
• * Severe dyspnea at rest
• * Oxygen-dependency
• No other malignancy except basal cell carcinoma of the skin
• No severe hypersensitivity to cetuximab or trastuzumab
• No medical or psychological condition that would preclude study completion or giving informed consent
• No legal incapacity or limited legal capacity
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior cetuximab or trastuzumab
• No other concurrent experimental drugs or anticancer therapy